<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/277" />
  <subtitle />
  <id>http://repository.usmf.md:80/handle/20.500.12710/277</id>
  <updated>2026-04-08T21:07:28Z</updated>
  <dc:date>2026-04-08T21:07:28Z</dc:date>
  <entry>
    <title>Particularităţi de afectare a pielii în patologia glandei tiroide</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/2036" />
    <author>
      <name>Vudu, Lorina</name>
    </author>
    <author>
      <name>Muravca, Tatiana</name>
    </author>
    <author>
      <name>Muravca, Alexei</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/2036</id>
    <updated>2019-06-22T14:23:20Z</updated>
    <published>2013-01-01T00:00:00Z</published>
    <summary type="text">Title: Particularităţi de afectare a pielii în patologia glandei tiroide
Authors: Vudu, Lorina; Muravca, Tatiana; Muravca, Alexei
Abstract: Skin is the organ where metabolic, circulatory and vegetative activities of the organism are&#xD;
expressed. Thyroid pathology has a higher prevalence during the last years and one of the organs&#xD;
where its dysfunction manifests is the skin. Thyroid hormones are involved in the maintainance&#xD;
of skin’s homeostasis, as well as in the homeostasis of the skin annexes and of the sebacious&#xD;
glands etc. Emphasyzing the pathologic skin semiology frequently leads to a correct&#xD;
endocrinologic diagnosis. &#xD;
&#xD;
&#xD;
Pielea este organul, la nivelul căruia este exprimată activitatea metabolică, circulatorie şi&#xD;
vegetativă a organismului. Patologia tiroidiană înregistrează o prevalenţă tot mai înaltă în ultimii&#xD;
ani şi unul din organele asupra căruia se manifestă disfuncţia ei este pielea. Hormonii tiroidieni&#xD;
sunt implicaţi în menţinerea homeostaziei pielii, fanerelor, glandelor sebacee etc. Evidenţierea&#xD;
semiologiei tegumentare patologice de cele mai multe ori orientează spre un diagnostic&#xD;
endocrinologic corect.
Description: Catedra Endocrinologie, USMF „Nicolae Testemiţanu”</summary>
    <dc:date>2013-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Structura şi particularităţile tabloului clinic al sindromului autoimun poliglandular</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/2037" />
    <author>
      <name>Vudu, Lorina</name>
    </author>
    <author>
      <name>Goian, Cristina</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/2037</id>
    <updated>2019-06-22T14:23:20Z</updated>
    <published>2013-01-01T00:00:00Z</published>
    <summary type="text">Title: Structura şi particularităţile tabloului clinic al sindromului autoimun poliglandular
Authors: Vudu, Lorina; Goian, Cristina
Abstract: Polyglandular autoimmune syndrome is a rare, but severe pathology, which occurs mostly&#xD;
in women. It has many signs, and each of them has its own clinical peculiarities. The endocrine&#xD;
glands are affected gradually. Patients with a single immune affected endocrine gland must be&#xD;
investigated for the presence of a polyglandular endocrine pathology. &#xD;
&#xD;
&#xD;
Sindromul autoimun poliglandular este o patologie rară, dar foarte gravă, cu afectarea&#xD;
preponderentă a sexului feminin. El este format din mai multe părți componente. Fiecare parte&#xD;
componentă prezintă un tablou clinic specific. Glandele endocrine se afectează nu simultan, ci&#xD;
după o anumită cosecutivitate în timp. Pacienții cu afectarea autoimună a unei glande endocrine&#xD;
ar trebui să fie investigați pentru afecțiunile de etiologie autoimună a altei glande endocrine.
Description: Catedra Endocrinologie USMF “NicolaeTestemițanu”</summary>
    <dc:date>2013-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Cardiomiopatia tireotoxică: particularităţi clinice</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/2038" />
    <author>
      <name>Vudu, Lorina</name>
    </author>
    <author>
      <name>Tudose, Tamara</name>
    </author>
    <author>
      <name>Muravca, Tatiana</name>
    </author>
    <author>
      <name>Cucu, Tatiana</name>
    </author>
    <author>
      <name>Cucu, Cristina</name>
    </author>
    <author>
      <name>Muravca, Alexei</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/2038</id>
    <updated>2019-06-22T14:23:20Z</updated>
    <published>2013-01-01T00:00:00Z</published>
    <summary type="text">Title: Cardiomiopatia tireotoxică: particularităţi clinice
Authors: Vudu, Lorina; Tudose, Tamara; Muravca, Tatiana; Cucu, Tatiana; Cucu, Cristina; Muravca, Alexei
Abstract: Thyrotoxic cardiomyopathy represents the myocardial injury caused by the toxic effects of&#xD;
the thyroid hormones. The duration of the thyrotoxicosis, the age and gender of the patient are&#xD;
important factors for the development of thyrotoxic cardiomyopathy and its clinical&#xD;
manifestations. Its most common symptoms are: palpitations, angina pectoris, dyspnoea and&#xD;
arrythmic heart contractions. The physical examination will frequently determine tachycardia,&#xD;
arrythmic heart contractions, systolic hypertension, orthostatic hypotension, enlargement of heart&#xD;
dullness at percussion, systolic murmurs and pulmonary rales (in case of heart failure).&#xD;
&#xD;
&#xD;
Cardiomiopatia tireotoxică reprezintă leziunea miocardului, cauzată de către efectele toxice&#xD;
ale hormonilor tiroidieni. Durata tireotoxicozei, vârsta şi sexul bolnavului reprezintă factori&#xD;
importanţi în dezvoltarea cardiomiopatiei tireotoxice şi manifestărilor ei clinice. Cele mai&#xD;
frecvente simptome ale cardiomiopatiei tireotoxice sunt palpitaţiile, angina pectorală, dispneea şi&#xD;
contracţiile cardiace aritmice. La examenul obiectiv deseori se atestă tahicardie, contracţii&#xD;
cardiace aritmice, hipertensiune sistolică, hipotensiune ortostatică, lărgirea matităţii cordului la&#xD;
percuţie, sufluri sistolice şi raluri pulmonare (în caz de insuficienţă cardiacă).
Description: Catedra Endocrinologie, USMF „Nicolae Testemiţanu”</summary>
    <dc:date>2013-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Hormonosubstituția pacienților cu hipotiroidie postoperatorie</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/2039" />
    <author>
      <name>Caradja, Gheorghe</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/2039</id>
    <updated>2019-06-22T14:23:20Z</updated>
    <published>2013-01-01T00:00:00Z</published>
    <summary type="text">Title: Hormonosubstituția pacienților cu hipotiroidie postoperatorie
Authors: Caradja, Gheorghe
Abstract: The study covers 96 patients with hypothyroidism, installed after surgical treatment of&#xD;
the nodular goiter.&#xD;
Was noticed that the thyroidal hormones substitution therapy is more efficient to&#xD;
administer to the patients with post-operation hypothyroidism, starting with the first week after&#xD;
the removal of at least of one quarter of the thyroidal tissue. The administred doze of thyroidal hormones, that compensates the post-operation hypothyroidism, will constitute app. 25 - 50 mkg/day of levotyroxin for every quarter of thyroidal tissue removed. &#xD;
&#xD;
&#xD;
Studiul cuprinde 96 pacienți cu hipotiroidie instalată după tratamentul chirurgical al&#xD;
gușilor nodulare.&#xD;
Sa observat că terapia de substituție cu hormoni tiroidieni este mai eficient de administrat&#xD;
pacienților cu hipotiroidie postoperatorie începând cu prima sâptămână de la înlăturarea a cel&#xD;
puțin un sfert de țesut tiroidian.&#xD;
Doza administrată de hormoni tiroidieni, care compensează hipotiroidia postoperatorie va&#xD;
constitui circa 25 – 50 mkg/zi de levotiroxină la fiecare sfert de țesut tiroidian înlăturat.
Description: Catedra Endocrinologie, USMF „Nicolae Testemiţanu”</summary>
    <dc:date>2013-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

